Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.
Also called NCT01869881
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 151 participants
- Sponsor
- Registry
-
NCT01869881
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01869881. Randomized; double masking; primary purpose treatment. Start 2013-02-01 (actual); primary completion 2014-11-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)
- Condition
- Diabetic Nephropathy
- Intervention (Drug)
- Anplag(Sarpogrelate)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Yuhan Corporation
Record details
- Record id
cardio:ct-nct01869881- Content hash
f5d84f00c9e72dbbb9213000c033cb3f12441629c369991f0db5e342a378dd71